文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

极低剂量玻璃体腔注射贝伐珠单抗治疗早产儿视网膜病变的短期结局

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

这项多中心、设盲、剂量递减研究纳入59例1型早产儿视网膜病变(ROP)患儿,每例单眼接受0.016、0.008、0.004或0.002 mg贝伐珠单抗注射。4周时0.016 mg和0.008 mg组成功率均为100%,0.004 mg组为90%,0.002 mg组仅74%,提示0.004 mg可能是有效的最低剂量。

要点

  • 0.016 mg和0.008 mg组4周成功率均为100%,0.004 mg组为90%,0.002 mg组为74%。
  • 0.004 mg可能是治疗1型ROP有效的最低贝伐珠单抗剂量。
  • 极低剂量贝伐珠单抗的有效性及其对血浆VEGF和外周视网膜血管化的影响需进一步研究确认。

核心结论

  • 0.004 mg可能是玻璃体腔注射贝伐珠单抗治疗1型ROP有效的最低剂量。

研究设计与样本

  • 2017年4月至2019年5月开展的多中心、设盲、剂量递减研究,纳入59例1型ROP早产儿。
  • 每例患儿单眼接受0.016、0.008、0.004或0.002 mg贝伐珠单抗注射,每组10至14例。

主要发现

  • 0.016 mg组13/13眼(100%)获得4周成功结局。
  • 0.008 mg组9/9眼(100%)获得4周成功结局。
  • 0.004 mg组9/10眼(90%)获得4周成功结局。
  • 0.002 mg组17/23眼(74%)获得4周成功结局。

关键数值与推荐

  • 成功定义为注射后4天病变改善,且4周内无1型ROP复发或需额外治疗的严重新生血管化。

临床怎么用

  • 极低剂量贝伐珠单抗可能用于1型ROP治疗,0.004 mg或是有效的最低剂量,但需进一步研究确认。

局限性

  • 样本量较小,每组仅10至14例。
  • 仅报告4周短期结局。
  • 未评估血浆血管内皮生长因子水平及外周视网膜血管化情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic toxicity, particularly the risk of neurodevelopmental delay. A much lower dose may be effective for ROP while reducing systemic risk. Previously, after testing doses of 0.25 mg to 0.031 mg, doses as low as 0.031 mg were found to be effective in small cohorts of infants. OBJECTIVE: To find the lowest dose of intravitreous bevacizumab effective for severe ROP. DESIGN, SETTING, AND PARTICIPANTS: Between April 2017 and May 2019, 59 premature infants with type 1 ROP in 1 or both eyes were enrolled in a masked, multicenter, dose de-escalation study. In cohorts of 10 to 14 infants, 1 eye per infant received 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg of intravitreous bevacizumab. Diluted bevacizumab was prepared by individual research pharmacies and delivered using 300-µL syringes with 5/16-inch, 30-guage fixed needles. Analysis began July 2019. INTERVENTIONS: Bevacizumab intravitreous injections at 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg. MAIN OUTCOMES AND MEASURES: Success was defined as improvement by 4 days postinjection and no recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks. RESULTS: Fifty-five of 59 enrolled infants had 4-week outcomes completed; the mean (SD) birth weight was 664 (258) g, and the mean (SD) gestational age was 24.8 (1.6) weeks. A successful 4-week outcome was achieved for 13 of 13 eyes (100%) receiving 0.016 mg, 9 of 9 eyes (100%) receiving 0.008 mg, 9 of 10 eyes (90%) receiving 0.004 mg, but only 17 of 23 eyes (74%) receiving 0.002 mg. CONCLUSIONS AND RELEVANCE: These data suggest that 0.004 mg may be the lowest dose of bevacizumab effective for ROP. Further investigation is warranted to confirm effectiveness of very low-dose intravitreous bevacizumab and its effect on plasma vascular endothelial growth factor levels and peripheral retinal vascularization.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wallace DK, Kraker RT, Freedman SF, et al. Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020. PMID: 32324197. doi:10.1001/jamaophthalmol.2020.0334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。